Test Catalog

Test ID: NONCP    
Neuro-Oncology Expanded Panel with Rearrangement, Tumor

Useful For Suggests clinical disorders or settings where the test may be helpful

Identifying mutations and rearrangements that may support a diagnosis for patients with tumors of the central nervous system (CNS)

 

Identifying mutations and rearrangements that may help determine prognosis for patients with tumors of the CNS

  

Identifying specific mutations and rearrangements within genes known to be associated with response or resistance to specific cancer therapies

Genetics Test Information Provides information that may help with selection of the correct genetic test or proper submission of the test request

This test uses targeted next-generation sequencing to evaluate for somatic mutations and rearrangements (fusions and abnormal transcript variants) involving 219 genes associated with tumors of the central nervous system. This panel includes a DNA subpanel for the detection of sequence alterations in 150 genes and an RNA subpanel for the detection of rearrangements in 81 genes, including 104 known gene fusions and 29 known abnormal transcript variants. See Targeted DNA Gene Regions Interrogated by Neuro-Oncology Panel and RNA Targeted Gene Fusions and Abnormal Transcript Variants in Special Instructions for details regarding the targeted gene regions identified by this test.

 

Of note, this test is performed to evaluate for somatic (ie, tumor-specific) mutations within the genes listed. Although germline (ie, inherited) alterations may be detected, this test cannot distinguish between germline and somatic alterations with absolute certainty. Follow-up germline testing using non-neoplastic (normal) tissue can be performed for confirmation of suspected clinically relevant germline alterations. Germline testing should be performed along with genetic counselling.

Highlights

This next-generation sequencing tumor profiling assay interrogates targeted gene regions and rearrangements across  219 genes associated with central nervous system tumors to assess for the presence of somatic mutations and rearrangements, including mutations in IDH1/2, TERT, ATRX, TP53, H3F3A, HIST1H3B/C, BRAF, SMARCB1, and SMARCA4, and rearrangements involving RELA, BRAF, and EGFR (eg, EGFR vIII).

Additional Tests Lists tests that are always performed, at an additional charge, with the initial tests.

Test IDReporting NameAvailable SeparatelyAlways Performed
SLIRVSlide Review in MGNo, (Bill Only)Yes

Testing Algorithm Delineates situations when tests are added to the initial order. This includes reflex and additional tests.

When this test is ordered, slide review will always be performed at an additional charge.

Special Instructions Library of PDFs including pertinent information and forms related to the test

Method Name A short description of the method used to perform the test

Polymerase Chain Reaction (PCR)-Based Next-Generation Sequencing (NGS)

NY State Available Indicates the status of NY State approval and if the test is orderable for NY State clients.

Yes

Reporting Name Lists a shorter or abbreviated version of the Published Name for a test

Neuro-Onc Expanded Panel

Aliases Lists additional common names for a test, as an aid in searching

ATRX
BRAF
Brain tumor
Central nervous system (CNS) cancers
EGFR
H3F3A
HIST1H3B
HIST1H3C
IDH1
IDH2
Next Gen Sequencing Test
NGS
Oncology panel
RELA
SMARCA4
SMARB1
TERT